EAF2 and malignant colon neoplasm: Additionally, our results also showed that EAF2 silencing did not sensitize another colon cancer cell line, HT-29 (which was considered relatively resistant to both simvastatin and lovastatin), suggesting the presence of a possible heterogeneity in genetic and molecular mechanisms involved in resistance to statins.